Saba Shaikh, MD

Saba Shaikh headshot
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Assistant Professor of Hematology/Oncology

Specialties

Clinical Locations

Educational Background

  • Chief Fellow Hematology/Oncology, University of Pittsburgh Medical Center Chief Fellow, 2021- 2022
  • Fellowship, Hematology/Oncology, University of Pittsburgh Medical Center Fellowship, 2019- 2022
  • Residency, Internal Medicine, McGaw Medical Center of Northwestern University Chicago, IL, 2017-2019
  • Internship, Internal Medicine, McGaw Medical Center of Northwestern University Internship, Chicago, IL, 2016-2017
  • M.D., Certificate in Medical Ethics, Baylor College of Medicine Houston, TX, 2012-2016
  • B.S. Neuroscience, University of Texas at Dallas Richardson, TX, 2008-2012

Certifications

  • American Board of Internal Medicine (Medicine), 2019
  • United States Medical Licensing Examination (Step 3), 2018
  • United States Medical Licensing Examination (Step 2 CK/CS), 2016
  • United States Medical Licensing Examination (Step 1), 2015

Memberships

  • Society for Immunotherapy of Cancer, 2020 – present
  • American Society of Hematology, 2019 – present
  • American Society of Clinical Oncology, 2019 – present
  • American College of Physicians, 2017 – present
  • American Medical Association, 2015 – present

Honors & Awards

  • Department of Medicine Fellow Teaching Competition Second Place, University of Pittsburgh Medical Center, 2020
  • Department of Medicine Research Day Second Place, Northwestern University, 2019
  • Resident Teaching Award, Northwestern University Feinberg School of Medicine, 2019
  • Resident Teaching Award, Northwestern University Feinberg School of Medicine, 2018
  • Resident Teaching Award, Northwestern University Feinberg School of Medicine, 2017
  • Brain and Behavioral Sciences Dean’s Scholar, University of Texas at Dallas, 2011-2012
  • Academic Honors Scholarship, University of Texas at Dallas, 2008-2012

Research Interests

  • Overcoming therapeutic resistance to immune checkpoint inhibitors in patients with advanced solid tumors 
  • Analysis of the immune response to novel therapeutic strategies in advanced solid tumors 
  • Quality of life assessments in patients with advanced solid tumors enrolled in clinical trials 

Selected Publications

Shaikh S, Kirkwood J. An open-label, dose-escalation phase Ib/II study to evaluate the safety, pharmacokinetics, and anti-tumor response of TAK-573 as a single agent and in combination with pembrolizumab. Regional Melanoma Translational Research Consortium Semiannual Meeting, February 2021. Virtual.

Najjar Y, Shaikh S, Bao R, Wang H, Davar D, Luke J, Zarour H, Kirkwood J, Delgoffe G. Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma. Melanoma Research Alliance Scientific Retreat, February 2021. Virtual.

Shaikh S, Kirkwood J. A phase I/II clinical study of VS-6766 plus pembrolizumab in patients with anti-PD1 refractory advanced melanoma. Regional Melanoma Translational Research Consortium Semiannual Meeting, August 2021. Virtual.

Shaikh S, Yang X, Fortman D, Wang H, Davar D, Luke J, Zarour H, Kirkwood J, Najjar Y. Impact of the COVID-19 Pandemic on Staging at Presentation of Patients with Invasive Melanoma. Journal of Clinical Oncology 2021 39:15_suppl, e21579-e21579.

Shaikh S, Zang Y, Hanmer J, Wang H, Ling Y, Davar D, Zarour H, Kirkwood J, Najjar Y. A Phase I Trial of Pembrolizumab plus Vemurafenib and Cobimetinib in Patients with Advanced Melanoma. Journal of Clinical Oncology 2021 39:15_suppl, e21506-e21506.

Shaikh S, Kamath S, Ghosh D, Lewandowski R, McMahon B. Safety and Outcomes of Permanent and Retrievable Filters in the Oncology Population. International Journal of Vascular Medicine. 2020: 6582742.

Shaikh S, Emens L. Current and Emerging Biologic Therapies for Triple Negative Breast Cancer. Expert Opinion on Biological Therapy. 2020; 1-12.

Shaikh S, Zang Y, Wang H, Yang X, Sander C, Rose A, Davar D, Luke J, Zarour H, Kirkwood J, Delgoffe G, Najjar Y. 435 A Phase II Trial of Nivolumab plus Axitinib in Patients with Anti-PD1 Refractory Advanced Melanoma. Journal for ImmunoTherapy of Cancer. 2020; 8: doi: 10.1136.

Shaikh S, Zang Y, Wang H, Yang X, Sander C, Rose A, Davar D, Luke J, Zarour H, Kirkwood J, Delgoffe G, Najjar Y. A Phase II Trial of Nivolumab plus Axitinib in Patients with Anti-PD1 Refractory Advanced Melanoma. Society for Immunotherapy of Cancer Annual Meeting, Nov 2020. Virtual.

Shaikh S, Kumthekar P, Mohindra N. A Review of Eligibility for Patients with Central Nervous System (CNS) Metastases from Non-Small Cell Lung cancer (NSCLC) in Immunotherapy Clinical Trials. Journal of Neurooncology. 2019; 144(1): 235-237... Expand

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
Resize Text

Related Articles